X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of this agreement, NKMax will be the study sponsor, and Merck KGaA, Darmstadt, Germany will supply cetuximab for a Phase I/IIa clinical trial in NSCLC patients for weekly dosing with 250 mg/m2 cetuximab administered by intravenous injection.
Lead Product(s): Autologous natural killer cells,Cetuximab,Gemcitabine
Therapeutic Area: Oncology Product Name: SNK01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2021
Details:
Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE®) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid tumors.
Lead Product(s): AFM24,SNK01
Therapeutic Area: Oncology Product Name: AFM24
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Affimed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2020
Details:
FDA has granted permission to amend its existing Phase I trial to add a new cohort of up to 18 patients to be treated with SNK01 in combination with either Pembrolizumab or Avelumab, two established checkpoint inhibitors.
Lead Product(s): Autologous natural killer cells,Avelumab
Therapeutic Area: Oncology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
The company plans to initiate a Phase 1/2a open-label, multi-center trial (Study SNK01-102) to evaluate the safety and anti-tumor activity of its expanded autologous natural killer cells in combination with trastuzumab or cetuximab in third quarter of this year.
Lead Product(s): SNK01,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
The abstract is based on a randomized phase I/IIa study to evaluate the safety and efficacy of SNK-01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) plus Pembrolizumab in patients with stage IV non-small cell lung cancer.
Lead Product(s): SNK-01,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Company to present three abstract titles related to SNK-01, an autologous NK cell adoptive immunotherapy for the upcoming 2020 American Society of Clinical Oncology (ASCO) annual meeting.
Lead Product(s): Autologous natural killer cells,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
